Get ebook downloads in full at ebookmeta.

com

Cancer Consult Expertise in Clinical Practice

Volume 1 Solid Tumors Supportive Care 2nd Edition
Syed A Abutalib Maurie Markman James O Armitage
Kenneth C Anderson Hope S Rugo Al B Benson Iii
https://ebookmeta.com/product/cancer-consult-expertise-in-
clinical-practice-volume-1-solid-tumors-supportive-care-2nd-
edition-syed-a-abutalib-maurie-markman-james-o-armitage-
kenneth-c-anderson-hope-s-rugo-al-b-benson-iii/

OR CLICK BUTTON

DOWNLOAD NOW

Explore and download more ebook at https://ebookmeta.com

 Recommended digital products (PDF, EPUB, MOBI) that
you can download immediately if you are interested.

Cancer Consult-Expertise in Clinical Practice, Volume

1-Solid Tumors & Supportive Care, 2e (Feb 5,
2024)_(1119823730)_(Wiley) 2nd Edition Syed A. Abutalib
https://ebookmeta.com/product/cancer-consult-expertise-in-clinical-
practice-volume-1-solid-tumors-supportive-
care-2e-feb-5-2024_1119823730_wiley-2nd-edition-syed-a-abutalib/
ebookmeta.com

Cancer Consult: Expertise in Clinical Practice, Volume 2:

Neoplastic Hematology & Cellular Therapy, 2nd Edition Syed
A. Abutalib
https://ebookmeta.com/product/cancer-consult-expertise-in-clinical-
practice-volume-2-neoplastic-hematology-cellular-therapy-2nd-edition-
syed-a-abutalib/
ebookmeta.com

Cancer Consult: Expertise in Clinical Practice, Volume 2:

Neoplastic Hematology & Cellular Therapy 2nd Edition S.
Abutalib
https://ebookmeta.com/product/cancer-consult-expertise-in-clinical-
practice-volume-2-neoplastic-hematology-cellular-therapy-2nd-edition-
s-abutalib/
ebookmeta.com

China s Contained Resource Curse How Minerals Shape State

Capital Labor Relations Jing Vivian Zhan

https://ebookmeta.com/product/china-s-contained-resource-curse-how-
minerals-shape-state-capital-labor-relations-jing-vivian-zhan/

ebookmeta.com
Harmony at the Piano: Using Keyboard Harmony to Learn
Advanced Piano Music [Team-IRA] 1st Edition Ken Johansen

https://ebookmeta.com/product/harmony-at-the-piano-using-keyboard-
harmony-to-learn-advanced-piano-music-team-ira-1st-edition-ken-
johansen/
ebookmeta.com

Globetrotter From Pioneer Digital Nomad to World s Most

Traveled Man 1st Edition Ian Boudreault

https://ebookmeta.com/product/globetrotter-from-pioneer-digital-nomad-
to-world-s-most-traveled-man-1st-edition-ian-boudreault/

ebookmeta.com

Peace Power and the United Nations A Security System for

the Twenty First Century 1st Edition Joseph P Lorenz

https://ebookmeta.com/product/peace-power-and-the-united-nations-a-
security-system-for-the-twenty-first-century-1st-edition-joseph-p-
lorenz/
ebookmeta.com

Holding Faith A Practical Introduction to Christian

Doctrine 1st Edition Cynthia L. Rigby

https://ebookmeta.com/product/holding-faith-a-practical-introduction-
to-christian-doctrine-1st-edition-cynthia-l-rigby/

ebookmeta.com

To Measure the Sky An Introduction to Observational

Astronomy Second Edition Instructor Res n 1 of 2 Solution
Manual Solutions Frederick R. Chromey
https://ebookmeta.com/product/to-measure-the-sky-an-introduction-to-
observational-astronomy-second-edition-instructor-
res-n-1-of-2-solution-manual-solutions-frederick-r-chromey/
ebookmeta.com
Public Reason and Political Autonomy: Realizing the Ideal
of a Civic People 1st Edition Blain Neufeld

https://ebookmeta.com/product/public-reason-and-political-autonomy-
realizing-the-ideal-of-a-civic-people-1st-edition-blain-neufeld/

ebookmeta.com
Cancer Consult
 Cancer Consult

Expertise in Clinical Practice, Second Edition.

Volume 1: Solid Tumors & Supportive Care

Edited by
Syed A. Abutalib, Maurie Markman, Al B. Benson III, and Hope S. Rugo

ffirs.indd 3 28-10-2023 11:33:35

 This second edition first published 2024
© 2024 John Wiley & Sons Ltd

Edition History
Cancer Consult: Expertise for Clinical Practice, John Wiley and Sons, Inc. (2014)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in
any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by
law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/
go/permissions.

The right of Syed A. Abutalib, Maurie Markman, Al B. Benson III and Hope S. Rugo to be identified as the
authors of the editorial material in this work has been asserted in accordance with law.

Registered Offices
John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at
www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that
appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or
its affiliates in the United States and other countries and may not be used without written permission. All other
trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product
or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion
only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis,
or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes
in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and
devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for
each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage
and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this
work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this
work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or
fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials
or promotional statements for this work. The fact that an organization, website, or product is referred to in this work
as a citation and/or potential source of further information does not mean that the publisher and authors endorse the
information or services the organization, website, or product may provide or recommendations it may make. This
work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and
strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate.
Further, readers should be aware that websites listed in this work may have changed or disappeared between when this
work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other
commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Abutalib, Syed A., editor. | Markman, Maurie, editor.
Title: Cancer consult : expertise in clinical practice. Volume 1, Solid tumors & supportive care / edited by
Syed A. Abutalib, Maurie Markman, Al B. Benson and Hope S. Rugo.
Description: Second edition. | Hokoben, NJ : John Wiley & Sons Ltd., 2023. | Includes bibliographical references.
Identifiers: LCCN 2023024465 | ISBN 9781119823735 (paperback) | ISBN 9781119823742 (pdf) | ISBN
9781119823759 (epub) | ISBN 9781119823766 (ebook)
Subjects: LCSH: Tumors--Treatment--Examinations, questions, etc.
Classification: LCC RC256 .C36 2023 | DDC 616.99/40076--dc23/eng/20230623
LC record available at https://lccn.loc.gov/2023024465

Cover image: © Kotkoa/Shutterstock

Cover design by Wiley

Set in 9.5/12.5pt STIXTwoText by Integra Software Services Pvt. Ltd, Pondicherry, India

ffirs.indd 4 28-10-2023 11:33:35

 v

Contents

Editors Volume 1 xi
Volume 2: Neoplastic Hematology & Cellular Therapy
Editors xii
Editor’s Biography xiii
Preface xv
Acknowledgment xvii

Part 1 Central Nervous System 1

1 Central Nervous System Tumors 3

Mark R. Gilbert and Edina Komlodi-Pasztor

Part 2 Head and Neck and Thoracic Cancers 13

2 Localized Head and Neck Cancer 15

Emrullah Yilmaz and Jessica L. Geiger

3 Recurrent and Metastatic Head and Neck Cancer 31

Chloe Weidenbaum and Mike Gibson

4 Thyroid Cancers 39
Kartik Sehgal and Jochen H. Lorch

5 Non-Small Cell Lung Cancer: Screening, Staging, and Stage I 51

Ryan D. Gentzler and Linda W. Martin

6 Non-Small Cell Lung Cancer: Stages II and III 63

Gregory Peter Kalemkerian, Kamya Sankar, and Angel Qin

7 Recurrent and Metastatic Non-Small Cell Lung Cancer 79

Julia Judd, J. Nicholas Bodor, and Hossein Borghaei

8 Small Cell Lung Cancer 97

Jyoti D. Patel and Husam Hafzah
vi Contents 

9 Mesothelioma 105
Harvey I. Pass, David Chen, and Jack Donaghue

Part 3 Breast Cancer 115

10 DCIS and LCIS 117

Amanda Nash, Rita Mukhtar, and Shelley Hwang

11 Early-Stage ER/PR–Positive, HER2-Negative Breast Cancer 129

William J. Gradishar

12 ER/PR-Positive, HER2-Negative Metastatic Breast Cancer 139

Sara Nunnery, Laura Kennedy, and Sonya Reid

13 Early-Stage HER2-Positive Breast Cancer 151

Erin Roesch and Jame Abraham

14 HER2-Positive Metastatic Breast Cancer 163

Reshma L. Mahtani, Naomi G. Dempsey, and Ana Sandoval

15 Early-Stage Triple-Negative Breast Cancer 179

Tiffany A. Traina, Carlos dos Anjos, and Elaine Walsh

16 Triple-Negative Metastatic Breast Cancer 191

Azadeh Nasrazadani, Juan Gomez, and Adam Brufsky

17 Inflammatory Breast Cancer – A Distinct Entity 201

Massimo Cristofanilli and Elena Vagia

18 Male Breast Cancer 213

Laura A. Huppert, Ozge Gumusay, Shreya Desai, and Hope S. Rugo

19 Breast Cancer in Pregnancy and Fertility Preservation 225

Fedro A. Peccatori, Hatem Azim, and Matteo Lambertini

Part 4 Gastrointestinal Cancers 233

20 Early-Stage Gastroesophageal Cancer and Precursor Lesions 235

Yixing Jiang and Aaron Ciner

21 Metastatic Esophagogastric Cancer 249

Geoffrey Y. Ku and David H. Ilson
 Contents  vii

22 Early-Stage Colon Cancer 255

John Krauss, Vaibhav Sahai, and Al B. Benson III

23 Early-Stage Rectal Cancer 267

Hannah J. Roberts, Theodore Hong, and Aparna Parikh

24 Recurrent and Metastatic Colorectal Cancer 283

Joseph Heng and Blase Polite

25 Pancreatic Adenocarcinoma 291

Evan Walker, Andrew Ko, and Margaret Tempero

26 Hepatocellular Cancer 309

Pedro Luiz Serrano Uson Junior and Mitesh Borad

27 Biliary Tract Cancers 319

David B. Zhen and Vaibhav Sahai

28 Carcinoid and Neuroendocrine Tumors 327

Mintallah Haider and Jonathan Strosberg

29 Anal Cancer 343

Asad Mahmood and Rob Glynne-Jones

Part 5 Genitourinary Cancers 359

30 Renal Cancer 361

James L. Coggan, Alan Tan, and Timothy M. Kuzel

31 Bladder Cancer 375

Revathi Kollipara, Alan Tan, and Timothy M. Kuzel

32 Prostate Cancer: Screening, Surveillance, Prognostic Algorithms,

and Independent Pathologic Predictive Parameters 389
Eduardo Benzi and Thomas M. Wheeler

33 Early and Locally Advanced Prostate Cancer 399

James Randall, Mohammad R. Siddiqui, Ashley Ross, and Sean Sachdev

34 Metastatic Prostate Cancer 421

Priyanka Chablani, Natalie Reizine, and Walter Stadler

35 Germ Cell Tumors 437

Hamid Emamekhoo, Syed A. Abutalib, and Timothy Gilligan
viii Contents 

Part 6 Skin Malignancies 453

36 Melanoma 455
Ana M. Ciurea and Kim Margolin

37 Nonmelanoma Skin Cancers 477

Chrysalyne D. Schmults and Danielle A. Parker

Part 7 Gynecological Cancers 497

38 Ovarian Cancer: Primary Treatment and Approach to Recurrent Disease 499

Rani Bansal, Don Dizon, and Martina Murphy

39 Ovarian Cancer: Second-line Treatment Strategies 511

Maurie Markman

40 Endometrial Cancer 523

Maurie Markman

41 Cancer of the Cervix, Vulva, and Vagina 533

Sabrina M. Bedell and Peter G. Rose

42 Uncommon Gynecologic Cancers 549

Michael Frumovitz, Shannon Westin, and David M. Gershenson

Part 8 Sarcomas 565

43 Bone Sarcomas 567

Nicole Larrier, William Eward, and Richard F. Riedel

44 Soft Tissue Sarcomas 579

Jeffrey Farma, Krisha Howell, and Margaret von Mehren

Part 9 Hereditary Cancer Syndromes and Genetic Testing 595

45 Hereditary Cancer Syndromes 597

Mary B. Daly

46 Hereditary Breast and Ovarian Cancer Syndromes 611

Kristen Whitaker and Elias Obeid

47 Hereditary Gastrointestinal and Pancreatic Cancer Syndromes 625

Kristen M. Shannon, Linda H. Rodgers-Fouche, and Daniel C. Chung
 Contents  ix

Part 10 Special Issues in Oncology 637

48 Cancer of Unknown Primary 639

Tony Greco

49 Anticoagulation in Cancer 651

Jean Marie Connors

50 Identification and Management of Immunotherapy-Related Adverse Events

in Oncology 663
Ozge Gumusay, Laura A. Huppert, Dame Idossa, and Hope S. Rugo

51 Geriatric Oncology 677

Sukeshi Patel Arora and Efrat Dotan

52 Palliative Medicine for Curable and Terminal Cancers 693

Isabelle Blanchard, Kavitha Jennifer Ramachandran, and Divya Gupta

Index 709
 xi

Editors Volume 1

Syed Ali Abutalib, MD Al B. Benson III, MD, FACP, FASCO

Medical Director Professor of Medicine
Hematologic Malignancies and Associate Director for Cooperative Groups
Transplantation and Cellular Therapy Robert H. Lurie Comprehensive Cancer
Aurora St. Luke’s Medical Center Center of Northwestern University
Advocate Aurora Health Care Chicago, IL
Milwaukee, Wisconsin
Hope S. Rugo, MD, FASCO
Maurie Markman, MD Professor of Medicine
Professor, Department of Medical Director, Breast Oncology and Clinical
Oncology and Therapeutics Research Trials Education
City of Hope University of California San Francisco
Helen Diller Family Comprehensive
President, Medicine & Science Cancer Center, San Francisco, CA
City of Hope, Atlanta,
Chicago and Phoenix

fbetw.indd 11 17-10-2023 18:39:22

 xii

Volume 2: Neoplastic Hematology & Cellular Therapy

Editors

Syed Ali Abutalib, MD Kenneth C. Anderson, MD

Medical Director Program Director, Jerome Lipper Multiple
Hematologic Malignancies and Myeloma Center and LeBow Institute for
Transplantation and Cellular Therapy Myeloma Therapeutics
Aurora St. Luke’s Medical Center Kraft Family Professor of Medicine
Advocate Aurora Health Care Harvard Medical School
Milwaukee, Wisconsin Dana Farber Cancer Institute, Boston, MA

Maurie Markman, MD James O. Armitage, MD

Professor, Department of Medical Joe Shapiro Professor of Medicine,
Oncology and Therapeutics Research University of Nebraska Medical Center
City of Hope Omaha, NE
President, Medicine & Science, City of
Hope, Atlanta, Chicago, and Phoenix

fbetw.indd 12 17-10-2023 18:39:22

 xiii

Editor’s Biography

Syed Ali Abutalib, MD, is Medical Director, Hematologic

Malignancies and Transplantation and Cellular Therapy,
Aurora St. Luke’s Medical Center. He also served as active
member of Executive Committee on Education for
American Society of Transplantation and Cellular therapy
(ASTCT®) and is one of the Associate Editors for The
ASCO Post®. Dr. Abutalib is the Founding Editor of
Advances in Cell and Gene Therapy, a Wiley Journal. In
addition, he is Associate Professor of Medicine at Rosalind
Franklin University of Medicine and Science. Dr. Abutalib
has ­co-edited 16 Hematology/Oncology and Cellular/
Gene therapy books over a short span of 10 years and has
published in a number of cancer magazines, journals, and textbooks. He continues to
collaborate with most cancer experts worldwide in the area of Hematology/Oncology
and stem cell transplantation to explore and develop innovative ideas and breakthroughs
in Medical Education with a prime focus to improve patient care.
Maurie Markman, MD, is Professor of Oncology and
Therapeutics Research, City of Hope and President of
Medicine & Science, City of Hope Atlanta, Chicago, Phoenix.
A nationally re­nowned oncologist, Dr. Markman has more
than 20 years of experience in cancer treatment and gyneco-
logic research at some of the country’s most recognized facil-
ities. Dr. Markman has served as the Vice President for
Clinical Research and Chairman of the Department of
Gynecologic Medical Oncology at M.D. Anderson Cancer
Center in Houston, Texas. Prior to that, Dr. Markman spent
11 years as Chairman of the Department of Hematology/
Oncology and Director of the Taussig Cancer Center at the
Cleveland Clinic Foundation. He also spent five years as
Vice Chairman of the Department of Medicine at Memorial
Sloan-Kettering Cancer Center in New York.
xiv Editor’s Biography

Al B. Benson III, M.D FACP FASCO is a Professor of

Medicine in the Division of Hematology/Oncology at
Northwestern University’s Feinberg School of Medicine in
Chicago, Illinois, and the Associate Director for Cooperative
Groups at the Robert H. Lurie Comprehensive Cancer
Center. He is a recipient of the American Society of Clinical
Oncology (ASCO) Statesman Award (Fellow of ASCO) and
has served on a number of ASCO committees, often as chair
or co-chair. Dr Benson is currently Vice-Chair of the ECOG-
ACRIN Cancer Research Group, past Chair of the ECOG-
ACRIN Gastrointestinal Committee, Co-Chair of Cancer
Care Delivery Research Committee, a member of the NCI
Rectal/Anal Task Force and Co-Chair of the International Rare Cancers Initiative (IRCI),
Anal Cancers Committee. In addition, he is a Past President of the Illinois Medical Oncology
Society, Past President of the Association of Community Cancer Centers (ACCC), a board
member and past-Chair of the Board of Directors of the National Comprehensive Cancer
Network (NCCN) and the past President of the National Patient Advocate Foundation. Dr.
Benson has published extensively in the areas of gastrointestinal cancer clinical trials, health
services research and cancer treatment guidelines.
Hope S. Rugo, MD, FASCO, is Director of Breast
Oncology and Clinical Trials Education and a Professor
of Medicine at the University of California San
Francisco Comprehensive Cancer Center. Dr. Rugo is
an internationally well-known medical oncologist spe-
cializing in breast cancer research and treatment. She
entered the field of breast cancer in order to incorporate
novel therapies with excellent quality of care into the
treatment of breast cancer and is a principal investigator
of multiple clinical trials focusing on novel targeted
therapeutics to improve the treatment of breast cancer. Her research interests include
immunotherapy and combinations of targeted agents to treat breast cancer, and
management of toxicity. She is co-chair of the Safety Committee for the multicenter adap-
tively randomized phase II I-SPY2 trial, co-chair of the Triple Negative Working Group of
the Translational Breast Cancer Research Consortium (TBCRC) and a member of the
Alliance breast committee. Dr. Rugo is an active clinician committed to education.
Other documents randomly have
different content
 *** END OF THE PROJECT GUTENBERG EBOOK LIFE AND
BLOODY CAREER OF THE EXECUTED CRIMINAL, JAMES
COPELAND, THE GREAT SOUTHERN LAND PIRATE ***

Updated editions will replace the previous one—the old editions will
be renamed.

Creating the works from print editions not protected by U.S.

copyright law means that no one owns a United States copyright in
these works, so the Foundation (and you!) can copy and distribute it
in the United States without permission and without paying copyright
royalties. Special rules, set forth in the General Terms of Use part of
this license, apply to copying and distributing Project Gutenberg™
electronic works to protect the PROJECT GUTENBERG™ concept
and trademark. Project Gutenberg is a registered trademark, and
may not be used if you charge for an eBook, except by following the
terms of the trademark license, including paying royalties for use of
the Project Gutenberg trademark. If you do not charge anything for
copies of this eBook, complying with the trademark license is very
easy. You may use this eBook for nearly any purpose such as
creation of derivative works, reports, performances and research.
Project Gutenberg eBooks may be modified and printed and given
away—you may do practically ANYTHING in the United States with
eBooks not protected by U.S. copyright law. Redistribution is subject
to the trademark license, especially commercial redistribution.

START: FULL LICENSE

THE FULL PROJECT GUTENBERG LICENSE
 PLEASE READ THIS BEFORE YOU DISTRIBUTE OR USE THIS WORK

To protect the Project Gutenberg™ mission of promoting the free

distribution of electronic works, by using or distributing this work (or
any other work associated in any way with the phrase “Project
Gutenberg”), you agree to comply with all the terms of the Full
Project Gutenberg™ License available with this file or online at
www.gutenberg.org/license.

Section 1. General Terms of Use and

Redistributing Project Gutenberg™
electronic works
1.A. By reading or using any part of this Project Gutenberg™
electronic work, you indicate that you have read, understand, agree
to and accept all the terms of this license and intellectual property
(trademark/copyright) agreement. If you do not agree to abide by all
the terms of this agreement, you must cease using and return or
destroy all copies of Project Gutenberg™ electronic works in your
possession. If you paid a fee for obtaining a copy of or access to a
Project Gutenberg™ electronic work and you do not agree to be
bound by the terms of this agreement, you may obtain a refund from
the person or entity to whom you paid the fee as set forth in
paragraph 1.E.8.

1.B. “Project Gutenberg” is a registered trademark. It may only be

used on or associated in any way with an electronic work by people
who agree to be bound by the terms of this agreement. There are a
few things that you can do with most Project Gutenberg™ electronic
works even without complying with the full terms of this agreement.
See paragraph 1.C below. There are a lot of things you can do with
Project Gutenberg™ electronic works if you follow the terms of this
agreement and help preserve free future access to Project
Gutenberg™ electronic works. See paragraph 1.E below.
1.C. The Project Gutenberg Literary Archive Foundation (“the
Foundation” or PGLAF), owns a compilation copyright in the
collection of Project Gutenberg™ electronic works. Nearly all the
individual works in the collection are in the public domain in the
United States. If an individual work is unprotected by copyright law in
the United States and you are located in the United States, we do
not claim a right to prevent you from copying, distributing,
performing, displaying or creating derivative works based on the
work as long as all references to Project Gutenberg are removed. Of
course, we hope that you will support the Project Gutenberg™
mission of promoting free access to electronic works by freely
sharing Project Gutenberg™ works in compliance with the terms of
this agreement for keeping the Project Gutenberg™ name
associated with the work. You can easily comply with the terms of
this agreement by keeping this work in the same format with its
attached full Project Gutenberg™ License when you share it without
charge with others.

1.D. The copyright laws of the place where you are located also
govern what you can do with this work. Copyright laws in most
countries are in a constant state of change. If you are outside the
United States, check the laws of your country in addition to the terms
of this agreement before downloading, copying, displaying,
performing, distributing or creating derivative works based on this
work or any other Project Gutenberg™ work. The Foundation makes
no representations concerning the copyright status of any work in
any country other than the United States.

1.E. Unless you have removed all references to Project Gutenberg:

1.E.1. The following sentence, with active links to, or other

immediate access to, the full Project Gutenberg™ License must
appear prominently whenever any copy of a Project Gutenberg™
work (any work on which the phrase “Project Gutenberg” appears, or
with which the phrase “Project Gutenberg” is associated) is
accessed, displayed, performed, viewed, copied or distributed:
 This eBook is for the use of anyone anywhere in the United
States and most other parts of the world at no cost and with
almost no restrictions whatsoever. You may copy it, give it away
or re-use it under the terms of the Project Gutenberg License
included with this eBook or online at www.gutenberg.org. If you
are not located in the United States, you will have to check the
laws of the country where you are located before using this
eBook.

1.E.2. If an individual Project Gutenberg™ electronic work is derived

from texts not protected by U.S. copyright law (does not contain a
notice indicating that it is posted with permission of the copyright
holder), the work can be copied and distributed to anyone in the
United States without paying any fees or charges. If you are
redistributing or providing access to a work with the phrase “Project
Gutenberg” associated with or appearing on the work, you must
comply either with the requirements of paragraphs 1.E.1 through
1.E.7 or obtain permission for the use of the work and the Project
Gutenberg™ trademark as set forth in paragraphs 1.E.8 or 1.E.9.

1.E.3. If an individual Project Gutenberg™ electronic work is posted

with the permission of the copyright holder, your use and distribution
must comply with both paragraphs 1.E.1 through 1.E.7 and any
additional terms imposed by the copyright holder. Additional terms
will be linked to the Project Gutenberg™ License for all works posted
with the permission of the copyright holder found at the beginning of
this work.

1.E.4. Do not unlink or detach or remove the full Project

Gutenberg™ License terms from this work, or any files containing a
part of this work or any other work associated with Project
Gutenberg™.

1.E.5. Do not copy, display, perform, distribute or redistribute this

electronic work, or any part of this electronic work, without
prominently displaying the sentence set forth in paragraph 1.E.1 with
active links or immediate access to the full terms of the Project
Gutenberg™ License.
1.E.6. You may convert to and distribute this work in any binary,
compressed, marked up, nonproprietary or proprietary form,
including any word processing or hypertext form. However, if you
provide access to or distribute copies of a Project Gutenberg™ work
in a format other than “Plain Vanilla ASCII” or other format used in
the official version posted on the official Project Gutenberg™ website
(www.gutenberg.org), you must, at no additional cost, fee or expense
to the user, provide a copy, a means of exporting a copy, or a means
of obtaining a copy upon request, of the work in its original “Plain
Vanilla ASCII” or other form. Any alternate format must include the
full Project Gutenberg™ License as specified in paragraph 1.E.1.

1.E.7. Do not charge a fee for access to, viewing, displaying,

performing, copying or distributing any Project Gutenberg™ works
unless you comply with paragraph 1.E.8 or 1.E.9.

1.E.8. You may charge a reasonable fee for copies of or providing

access to or distributing Project Gutenberg™ electronic works
provided that:

• You pay a royalty fee of 20% of the gross profits you derive from
the use of Project Gutenberg™ works calculated using the
method you already use to calculate your applicable taxes. The
fee is owed to the owner of the Project Gutenberg™ trademark,
but he has agreed to donate royalties under this paragraph to
the Project Gutenberg Literary Archive Foundation. Royalty
payments must be paid within 60 days following each date on
which you prepare (or are legally required to prepare) your
periodic tax returns. Royalty payments should be clearly marked
as such and sent to the Project Gutenberg Literary Archive
Foundation at the address specified in Section 4, “Information
about donations to the Project Gutenberg Literary Archive
Foundation.”

• You provide a full refund of any money paid by a user who

notifies you in writing (or by e-mail) within 30 days of receipt that
s/he does not agree to the terms of the full Project Gutenberg™
License. You must require such a user to return or destroy all
 copies of the works possessed in a physical medium and
discontinue all use of and all access to other copies of Project
Gutenberg™ works.

• You provide, in accordance with paragraph 1.F.3, a full refund of

any money paid for a work or a replacement copy, if a defect in
the electronic work is discovered and reported to you within 90
days of receipt of the work.

• You comply with all other terms of this agreement for free
distribution of Project Gutenberg™ works.

1.E.9. If you wish to charge a fee or distribute a Project Gutenberg™

electronic work or group of works on different terms than are set
forth in this agreement, you must obtain permission in writing from
the Project Gutenberg Literary Archive Foundation, the manager of
the Project Gutenberg™ trademark. Contact the Foundation as set
forth in Section 3 below.

1.F.

1.F.1. Project Gutenberg volunteers and employees expend

considerable effort to identify, do copyright research on, transcribe
and proofread works not protected by U.S. copyright law in creating
the Project Gutenberg™ collection. Despite these efforts, Project
Gutenberg™ electronic works, and the medium on which they may
be stored, may contain “Defects,” such as, but not limited to,
incomplete, inaccurate or corrupt data, transcription errors, a
copyright or other intellectual property infringement, a defective or
damaged disk or other medium, a computer virus, or computer
codes that damage or cannot be read by your equipment.

1.F.2. LIMITED WARRANTY, DISCLAIMER OF DAMAGES - Except

for the “Right of Replacement or Refund” described in paragraph
1.F.3, the Project Gutenberg Literary Archive Foundation, the owner
of the Project Gutenberg™ trademark, and any other party
distributing a Project Gutenberg™ electronic work under this
agreement, disclaim all liability to you for damages, costs and
expenses, including legal fees. YOU AGREE THAT YOU HAVE NO
REMEDIES FOR NEGLIGENCE, STRICT LIABILITY, BREACH OF
WARRANTY OR BREACH OF CONTRACT EXCEPT THOSE
PROVIDED IN PARAGRAPH 1.F.3. YOU AGREE THAT THE
FOUNDATION, THE TRADEMARK OWNER, AND ANY
DISTRIBUTOR UNDER THIS AGREEMENT WILL NOT BE LIABLE
TO YOU FOR ACTUAL, DIRECT, INDIRECT, CONSEQUENTIAL,
PUNITIVE OR INCIDENTAL DAMAGES EVEN IF YOU GIVE
NOTICE OF THE POSSIBILITY OF SUCH DAMAGE.

1.F.3. LIMITED RIGHT OF REPLACEMENT OR REFUND - If you

discover a defect in this electronic work within 90 days of receiving it,
you can receive a refund of the money (if any) you paid for it by
sending a written explanation to the person you received the work
from. If you received the work on a physical medium, you must
return the medium with your written explanation. The person or entity
that provided you with the defective work may elect to provide a
replacement copy in lieu of a refund. If you received the work
electronically, the person or entity providing it to you may choose to
give you a second opportunity to receive the work electronically in
lieu of a refund. If the second copy is also defective, you may
demand a refund in writing without further opportunities to fix the
problem.

1.F.4. Except for the limited right of replacement or refund set forth in
paragraph 1.F.3, this work is provided to you ‘AS-IS’, WITH NO
OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR ANY PURPOSE.

1.F.5. Some states do not allow disclaimers of certain implied

warranties or the exclusion or limitation of certain types of damages.
If any disclaimer or limitation set forth in this agreement violates the
law of the state applicable to this agreement, the agreement shall be
interpreted to make the maximum disclaimer or limitation permitted
by the applicable state law. The invalidity or unenforceability of any
provision of this agreement shall not void the remaining provisions.
1.F.6. INDEMNITY - You agree to indemnify and hold the
Foundation, the trademark owner, any agent or employee of the
Foundation, anyone providing copies of Project Gutenberg™
electronic works in accordance with this agreement, and any
volunteers associated with the production, promotion and distribution
of Project Gutenberg™ electronic works, harmless from all liability,
costs and expenses, including legal fees, that arise directly or
indirectly from any of the following which you do or cause to occur:
(a) distribution of this or any Project Gutenberg™ work, (b)
alteration, modification, or additions or deletions to any Project
Gutenberg™ work, and (c) any Defect you cause.

Section 2. Information about the Mission of

Project Gutenberg™
Project Gutenberg™ is synonymous with the free distribution of
electronic works in formats readable by the widest variety of
computers including obsolete, old, middle-aged and new computers.
It exists because of the efforts of hundreds of volunteers and
donations from people in all walks of life.

Volunteers and financial support to provide volunteers with the

assistance they need are critical to reaching Project Gutenberg™’s
goals and ensuring that the Project Gutenberg™ collection will
remain freely available for generations to come. In 2001, the Project
Gutenberg Literary Archive Foundation was created to provide a
secure and permanent future for Project Gutenberg™ and future
generations. To learn more about the Project Gutenberg Literary
Archive Foundation and how your efforts and donations can help,
see Sections 3 and 4 and the Foundation information page at
www.gutenberg.org.

Section 3. Information about the Project

Gutenberg Literary Archive Foundation
The Project Gutenberg Literary Archive Foundation is a non-profit
501(c)(3) educational corporation organized under the laws of the
state of Mississippi and granted tax exempt status by the Internal
Revenue Service. The Foundation’s EIN or federal tax identification
number is 64-6221541. Contributions to the Project Gutenberg
Literary Archive Foundation are tax deductible to the full extent
permitted by U.S. federal laws and your state’s laws.

The Foundation’s business office is located at 809 North 1500 West,

Salt Lake City, UT 84116, (801) 596-1887. Email contact links and up
to date contact information can be found at the Foundation’s website
and official page at www.gutenberg.org/contact

Section 4. Information about Donations to

the Project Gutenberg Literary Archive
Foundation
Project Gutenberg™ depends upon and cannot survive without
widespread public support and donations to carry out its mission of
increasing the number of public domain and licensed works that can
be freely distributed in machine-readable form accessible by the
widest array of equipment including outdated equipment. Many small
donations ($1 to $5,000) are particularly important to maintaining tax
exempt status with the IRS.

The Foundation is committed to complying with the laws regulating

charities and charitable donations in all 50 states of the United
States. Compliance requirements are not uniform and it takes a
considerable effort, much paperwork and many fees to meet and
keep up with these requirements. We do not solicit donations in
locations where we have not received written confirmation of
compliance. To SEND DONATIONS or determine the status of
compliance for any particular state visit www.gutenberg.org/donate.

While we cannot and do not solicit contributions from states where

we have not met the solicitation requirements, we know of no
prohibition against accepting unsolicited donations from donors in
such states who approach us with offers to donate.

International donations are gratefully accepted, but we cannot make

any statements concerning tax treatment of donations received from
outside the United States. U.S. laws alone swamp our small staff.

Please check the Project Gutenberg web pages for current donation
methods and addresses. Donations are accepted in a number of
other ways including checks, online payments and credit card
donations. To donate, please visit: www.gutenberg.org/donate.

Section 5. General Information About Project

Gutenberg™ electronic works
Professor Michael S. Hart was the originator of the Project
Gutenberg™ concept of a library of electronic works that could be
freely shared with anyone. For forty years, he produced and
distributed Project Gutenberg™ eBooks with only a loose network of
volunteer support.

Project Gutenberg™ eBooks are often created from several printed

editions, all of which are confirmed as not protected by copyright in
the U.S. unless a copyright notice is included. Thus, we do not
necessarily keep eBooks in compliance with any particular paper
edition.

Most people start at our website which has the main PG search
facility: www.gutenberg.org.

This website includes information about Project Gutenberg™,

including how to make donations to the Project Gutenberg Literary
Archive Foundation, how to help produce our new eBooks, and how
to subscribe to our email newsletter to hear about new eBooks.